Bad news!
"A decade of axed clinical trials in review
Between 2013 and 2023, the proportion of phase II and phase III trials that were cut more than doubled, according to an analysis by four researchers at Epistemic AI, a research-intelligence platform for biomedicine.
The reasons revolved around the performance of competitors, the drug performing better for other disorders, changes in the perceived money-making potential of the drug, changes in sponsor funding and changes in aims following mergers, acquisitions or licensing deals. Better understanding of these decisions could help cut wasted investment, argue the authors."
No comments:
Post a Comment